Evaxion to present new data at AACR Annual Meeting

Core Insights - Evaxion A/S, a clinical-stage TechBio company, is set to present two abstracts at the AACR Annual Meeting in April 2026, focusing on its AI-Immunology™ platform and personalized cancer vaccines [1][6]. Group 1: Abstract Presentations - The first abstract will present new biomarker and immunogenicity data for the personalized cancer vaccine EVX-01, which is currently being evaluated for advanced melanoma treatment [2][3]. - The second abstract will discuss the identification of endogenous retrovirus-derived neoantigens for personalized vaccines targeting glioblastoma, a type of brain cancer with limited treatment options [4][6]. Group 2: Clinical Trials and Collaborations - The data for EVX-01 comes from a phase 2 trial that combines the vaccine with MSD's KEYTRUDA® therapy in patients with advanced melanoma, where each vaccine is tailored to the individual patient's biology [3]. - Evaxion will also engage in the AACR Oncology Industry Partnering event to explore potential business partnerships and scientific collaborations [4][6]. Group 3: Company Overview - Evaxion utilizes its proprietary AI-Immunology™ platform to develop novel vaccine candidates for cancer and infectious diseases, emphasizing rapid and efficient target discovery and drug design [7]. - The company has a clinical pipeline that includes both personalized and off-the-shelf cancer vaccine candidates, addressing significant unmet medical needs [7].